Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311747523> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4311747523 abstract "Abstract Background Difficult-to-treat resistant (DTR) isolates are defined as resistance to all first-line high-efficacy, low-toxicity antibiotics (penicillins, cephalosporins, carbapenems and quinolones), leaving physicians with limited treatment options. Cefiderocol (CFDC) is a siderophore cephalosporin with activity against a wide variety of Gram-negative bacteria, including carbapenem-resistant Enterobacterales and non-fermenters. We evaluated the in vitro activity of cefiderocol against DTR isolates collected in United States as part of SENTRY surveillance program in 2020 and 2021. In vitro susceptibility of cefiderocol and comparator agents to DTR isolates Methods Susceptibility testing was performed by broth microdilution according to CLSI guidelines. All antibiotics were tested in cation-adjusted Mueller-Hinton broth (CAMHB) except for CFDC, for which iron-depleted CAMHB was used. Susceptibility rate (%) was determined according to CLSI breakpoints, and DTR pathogens were defined as being resistant to cefepime, ceftazidime ceftriaxone (only for Enterobacterales), imipenem, meropenem, ciprofloxacin and levofloxacin according to CLSI/FDA breakpoints. Results Among a total of 8,328 Enterobacterales, 2,241 Pseudomonas aeruginosa, and 586 Acinetobacter calcoaceticus-baumannii complex (ACB) clinical isolates from the United States, 50 Enterobacterales (0.6%), 36 P. aeruginosa (1.6%) and 114 ACB (19.5%) isolates showed a DTR phenotype, respectively. CFDC demonstrated its potent in vitro activity against these DTR isolates with MIC90 of ≤4 μg/mL with a susceptibility rate of ≥92% except for DTR ACB based on FDA breakpoint (75.4%). In contrast, MIC90s of β-lactam/β-lactamase inhibitor combination drugs showed lower activity (Table). Conclusion Cefiderocol demonstrated potent in vitro activity against DTR isolates of Enterobacterales, P. aeruginosa and ACB, indicating cefiderocol has high potential for treating infections caused by these difficult-to-treat strains. Disclosures Yoshinori Yamano, PhD, Shionogi: Employee Miki Takemura, n/a, Shionogi: Employee Dee Shortridge, PhD, AbbVie: Grant/Research Support|JMI Laboratory: Employee|Melinta: Grant/Research Support|Menarini: Grant/Research Support|Shionogi: Grant/Research Support Christine M. Slover, PharmD, Shionogi: Employee Christopher M. Longshaw, PhD, Shionogi: Employee Roger Echols, MD, Shionogi: Advisor/Consultant Roger Echols, MD, Shionogi: Advisor/Consultant Roger Echols, MD, Shionogi: Advisor/Consultant." @default.
- W4311747523 created "2022-12-28" @default.
- W4311747523 creator A5005375645 @default.
- W4311747523 creator A5028735988 @default.
- W4311747523 creator A5032440208 @default.
- W4311747523 creator A5050331950 @default.
- W4311747523 creator A5055866273 @default.
- W4311747523 creator A5068245967 @default.
- W4311747523 date "2022-12-01" @default.
- W4311747523 modified "2023-09-30" @default.
- W4311747523 title "1715. In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021" @default.
- W4311747523 doi "https://doi.org/10.1093/ofid/ofac492.1345" @default.
- W4311747523 hasPublicationYear "2022" @default.
- W4311747523 type Work @default.
- W4311747523 citedByCount "0" @default.
- W4311747523 crossrefType "journal-article" @default.
- W4311747523 hasAuthorship W4311747523A5005375645 @default.
- W4311747523 hasAuthorship W4311747523A5028735988 @default.
- W4311747523 hasAuthorship W4311747523A5032440208 @default.
- W4311747523 hasAuthorship W4311747523A5050331950 @default.
- W4311747523 hasAuthorship W4311747523A5055866273 @default.
- W4311747523 hasAuthorship W4311747523A5068245967 @default.
- W4311747523 hasBestOaLocation W43117475231 @default.
- W4311747523 hasConcept C176947019 @default.
- W4311747523 hasConcept C2776315533 @default.
- W4311747523 hasConcept C2776685102 @default.
- W4311747523 hasConcept C2776968632 @default.
- W4311747523 hasConcept C2777050379 @default.
- W4311747523 hasConcept C2777637488 @default.
- W4311747523 hasConcept C2778512257 @default.
- W4311747523 hasConcept C2779375183 @default.
- W4311747523 hasConcept C2779631663 @default.
- W4311747523 hasConcept C2780950330 @default.
- W4311747523 hasConcept C4937899 @default.
- W4311747523 hasConcept C501593827 @default.
- W4311747523 hasConcept C523546767 @default.
- W4311747523 hasConcept C54355233 @default.
- W4311747523 hasConcept C64778159 @default.
- W4311747523 hasConcept C71924100 @default.
- W4311747523 hasConcept C86803240 @default.
- W4311747523 hasConcept C89423630 @default.
- W4311747523 hasConcept C94665300 @default.
- W4311747523 hasConceptScore W4311747523C176947019 @default.
- W4311747523 hasConceptScore W4311747523C2776315533 @default.
- W4311747523 hasConceptScore W4311747523C2776685102 @default.
- W4311747523 hasConceptScore W4311747523C2776968632 @default.
- W4311747523 hasConceptScore W4311747523C2777050379 @default.
- W4311747523 hasConceptScore W4311747523C2777637488 @default.
- W4311747523 hasConceptScore W4311747523C2778512257 @default.
- W4311747523 hasConceptScore W4311747523C2779375183 @default.
- W4311747523 hasConceptScore W4311747523C2779631663 @default.
- W4311747523 hasConceptScore W4311747523C2780950330 @default.
- W4311747523 hasConceptScore W4311747523C4937899 @default.
- W4311747523 hasConceptScore W4311747523C501593827 @default.
- W4311747523 hasConceptScore W4311747523C523546767 @default.
- W4311747523 hasConceptScore W4311747523C54355233 @default.
- W4311747523 hasConceptScore W4311747523C64778159 @default.
- W4311747523 hasConceptScore W4311747523C71924100 @default.
- W4311747523 hasConceptScore W4311747523C86803240 @default.
- W4311747523 hasConceptScore W4311747523C89423630 @default.
- W4311747523 hasConceptScore W4311747523C94665300 @default.
- W4311747523 hasIssue "Supplement_2" @default.
- W4311747523 hasLocation W43117475231 @default.
- W4311747523 hasLocation W43117475232 @default.
- W4311747523 hasOpenAccess W4311747523 @default.
- W4311747523 hasPrimaryLocation W43117475231 @default.
- W4311747523 hasRelatedWork W1788363151 @default.
- W4311747523 hasRelatedWork W2067101411 @default.
- W4311747523 hasRelatedWork W2105640536 @default.
- W4311747523 hasRelatedWork W2391243184 @default.
- W4311747523 hasRelatedWork W2739586875 @default.
- W4311747523 hasRelatedWork W2945165328 @default.
- W4311747523 hasRelatedWork W3001558422 @default.
- W4311747523 hasRelatedWork W3006346950 @default.
- W4311747523 hasRelatedWork W3133065925 @default.
- W4311747523 hasRelatedWork W3137608310 @default.
- W4311747523 hasVolume "9" @default.
- W4311747523 isParatext "false" @default.
- W4311747523 isRetracted "false" @default.
- W4311747523 workType "article" @default.